 | Up a level |
Journal Article
Faehling, M., Schumann, C., Christopoulos, P., Hoffknecht, P., Alt, J., Horn, M., Eisenmann, S., Schlenska-Lange, A., Aries, S. P., Sackmann, S., Schuett, P., Steger, F. and Christoph, D. (2020). Durvalumab after definitive radiochemotherapy (RCT) in locally advanced unresectable NSCLC: Real-world data on survival and safety from the German expanded access program (EAP). Ann. Oncol., 31. S. S806 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Roeper, J., Lueers, A., Netchaeva, M., Falk, M., Hallas, C., Tiemann, M., Neemann, N., Heukamp, L., Wesseler, C., Wiest, G. H., Ukena, D., Sackmann, S. and Griesinger, F. (2017). Impact on OS and PFS of 2nd and 3rd generation TKI in EGFR mt1 and ALK1 pts: Results of the NOWEL network. Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Stratmann, J. A., Hornetz, S., Griesinger, F., Wolf, J., Christoph, D. C., Sackmann, S., Spengler, W., Bischoff, H., Schaefer, M., Alt, J., Mlueller, A., Laack, E., Kimmich, M. and Sebastian, M. (2017). An expanded access program of osimertinib (Tagrisso) in patients with advanced non-small cell lung cancer: data report from Germany. Oncol. Res. Treat., 40. S. 170 - 171. BASEL: KARGER. ISSN 2296-5262